Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Christine Pfaff on Ensuring Patient Access to Affordable Treatments
October 17th 2023To ensure patients are getting timely access to their treatments, there needs to be better collaboration between payers and providers, said Christine Pfaff, RPh, senior regional director of operations, American Oncology Network.
Read More
FDA Grants Pembrolizumab Sixth Indication in NSCLC
October 17th 2023The anti–PD-1 agent pembrolizumab was granted a new indication to treat patients with resectable non–small cell lung cancer (NSCLC) as a neoadjuvant treatment with chemotherapy and continued as adjuvant treatment after surgery.
Read More
Patient, Provider Education and Payer Management Can Improve Biosimilar Uptake: Dr Bincy Abraham
October 15th 2023Biosimilars are becoming more common as more launch on the market in the United States, but patient and provider education can help speed uptake of these products, explained Bincy Abraham, MD, Houston Methodist – Weill Cornell.
Read More
Novel Approaches to Head and Neck Cancer at Vanderbilt Ingram Cancer Center
October 12th 2023Speakers at an Institute for Value-Based Medicine event with Vanderbilt University Medical Center highlighted the novel therapies and techniques being used to improve outcomes for patients with head and neck cancer.
Read More
Updates Are Driving the Field of MDS Forward, but Changes Still Needed
September 25th 2023In just the last 2 years there have been updates in classification, risk assessment, and response criteria in myelodysplastic syndromes (MDS), but additional efforts are needed to improve these, and there remains a need for better therapies.
Read More
Biosimilars Had a Huge Impact on Total Cost of Care, Says AON’s Christine Pfaff
September 23rd 2023In a few short years, biosimilars have driven down total cost of care in oncology through providing competition for expensive drugs, explained Christine Pfaff, RPh, senior regional director of operations, American Oncology Network (AON).
Read More
Study Highlights Association of COPD and CVDs, Need for Prevention and Management
September 22nd 2023Among adults 40 years and older with chronic obstructive pulmonary disease (COPD), there is a higher prevalence of cardiovascular diseases (CVDs) compared with a general population without COPD.
Read More
Switching Back to Originator From Biosimilar Infliximab Results in Higher Discontinue Rates
September 16th 2023One-fourth of patients who switched to an infliximab biosimilar retransitioned back to the originator, but they were more likely to subsequently discontinue treatment due to an unwanted response after switching back.
Read More
Regional Disparities Remain in Breast Reconstruction for Patients With Breast Cancer
September 15th 2023While regional variations were identified in rates of breast reconstruction, complications, and cost for patients with breast cancer, these differences did not seem to be associated with any implicit bias.
Read More
Laura Wingate: Biosimilars Can Improve Access to Treatment for Patients
September 3rd 2023Biosimilars can improve access to treatment for patients who might not have been able to access biologics previously, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Read More
Laura Wingate Discusses Patient Education for Biosimilar Switches vs New Starts, Interchangeability
August 15th 2023Greater attention needs to be on educating patients who are switching from a reference product they are successful on to a biosimilar than a patient who is starting a treatment with a biosimilar at the beginning of their disease journey, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Read More
Delays Between CRC Presentation, Treatment Not Associated With Poor Survival in Young Adults
August 3rd 2023Adults younger than 50 years with colorectal cancer (CRC) who experience postpresentation delays in treatment did not appear to have worse outcomes, according to a study in Ontario, Canada.
Read More
Laura Wingate: Education Makes Patients More Confident in Biosimilar Switches
August 3rd 2023There is a right way and a wrong way to inform a patient about a switch from the reference product to a biosimilar, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Read More
Dr Haley Naik: Improved Medical Education Can Help Reduce Diagnostic Delays of HS
July 30th 2023Some populations face longer diagnostic delays for hidradenitis suppurativa (HS), but medical education can help improve knowledge of common dermatologic diseases and reduce delays in diagnosis, said Haley Naik, MD, FAAD, associate professor of dermatology, University of California, San Francisco, School of Medicine.
Read More